ThePlatform.ie – Ireland’s Solution Resource.
All you need to know about the Lockdown & the Virus!
Interview; Dave Cullen with Prof. Dolores J. Cahill, Professor of Translational Science at UCD School of Medicine, University College Dublin. Prof. Dr. Cahill has over 25 years expertise in high-throughput protein array, antibody array, proteomics technology development.
A world-leading scientist and academic. She is renowned for her work in Bio-Medicine. She has been a member of the Advisory Science Council to the Irish Government and a member of the International Science Advisory Board. Read her full bio at the end of this page.
Dr. Zach Bush, MD
Are Covid-19 Patients mismanaged and treated? | Dr. Zach Bush, MD
German Official Leaks Report Denouncing Corona as ‘A Global False Alarm’
PLANDEMIC DOCUMENTARY (PART 1) – Dr. JUDY MIKOVITS:
Dr. Scott Jensen questions what he’s told by the Dept. of Health to put on death certs & the data used in the modelling.
Lifting the Lockdown with Prof. Dolores Cahill, Dr. Judy Mikovit & Dr. Sherri Tenpenny
Prof. Dolores J. Cahill Interview with Del Bigtree
Prof. Dolores J. Cahill – Full Bio
Prof. Dolores J. Cahill, Professor of Translational Science at UCD School of Medicine, University College Dublin Prof. Dr. Dolores Cahill has over 25 years expertise in high-throughput protein array, antibody array, proteomics technology development,automation and their biomedical applications, including in biomarker discovery, diagnostics and personalised medicine. She is Professor of Translational Science, School of Medicine and at the Conway Institute at the University College Dublin (UCD) (2005-present). With her research group & collaborators, she has achieved key breakthroughs in developing and demonstrating applications of high throughput array technology in biological, diagnostics & medical research.
Prof. Cahill pioneered this research at the Max-Planck-Institute of Molecular Genetics in Berlin, Germany (1996-2003) and holds several granted international patents in this vital field. Some of her activities include: In 1996, she co-founded Protagen AG (https://protagen.com/) in Dortmund, including with Prof. Helmut Meyer, as a spin-out of the Max-Planck-Institute to commercialise her discoveries. Protagen Protein Services (https://protagenproteinservices.com/) a 2014 spin-off company of Protagen delivers expert protein, antibody, proteomics & peptide contract services to the pharmaceutical industry & health care sectors. Both companies have advanced these technologies & applications; Protagen has screened and profiled the autoantibody repertoire of over 20,000 patients (https://protagen.com/data-and-insight…). Protagen AG and Protagen Protein Services have over 200 employees in 2018. Since 2016, Prof. Cahill is a shareholder & Advisory Board member of Atturos Ltd, Prof. Stephen Pennington’s UCD spin-out company nvolved in improved Prostate Cancer diagnosis (http://atturos.com/ and http://atturos.com/company/advisors/).
She received her Honours degree in Molecular Genetics from Trinity College Dublin (1989) and her PhD in Immunology from Dublin City University (1994). While studying in Trinity, she was awarded the Irish American Fellowship Prize (1988) to research at Prof. Pringle’s laboratory in the University of Michigan, Ann Arbor, USA. During her undergraduate & PhD studies, she worked, including as Assistant Manager, in fine-dining Country Clubs in Long Island, New York (4 summers) & in Tenafly, New Jersey (4 summers). On obtaining her PhD, she obtained an EU ‘Human Capital & Mobility’ Post-doctoral Fellowship at the Technical University, Munich, Germany (1994-1995). Prof. Cahill became Group Leader of the Protein Technology Group in the Max-Planck-Institute of Molecular Genetics, Berlin (1996-2003). She obtained an Associate Professor position, in the Department of Clinical Pharmacology and Director of Proteomics Core, RCSI, Dublin (2000-2005). Since 2005 – present, she is Full Professor of Translational Science in the School of Medicine, University College Dublin and she has extensive management experience, including successfully obtaining funding from the European Commission (FP4, FP5, FP6, FP7 and Horizon 2020), Science Foundation Ireland, Enterprise Ireland, Health Research Board & successfully writing, project managing, publishing & reporting on all financial & regulatory aspects in academic & private sectors, in the companies she co-founded.
She has over 100 peer reviewed publications, with over 5000 citations and a H-index is 31, which is in the top 10% globally for the Biomedicine discipline. Prof. Cahill is internationally recognised for her biomedical research, publications and patent record in life sciences, biotechnology, personalised healthcare, personalised medicine, diagnostics, biomarker discovery and validation, proteomics, biotechnology, high content protein and antibody arrays and their biomedical, diagnostic and clinical applications. Her publications have demonstrated utility and applications in the research, commercial & clinical sectors and include characterisation of antibodies specificity (including therapeutic antibodies), biomarker discovery, diagnostics, assay development, protein-interaction studies, proteomics, large scale/systems biology research, validating biomarker panels in diagnostic clinical trial, personalised medicine and assessing immune related adverse events.
She has given over 100 Keynotes Lectures in Ireland, UK, Europe, USA, China, Japan, South Korea, Australia, South America. For example, she is invited to the ‘5th Precision Medicine and Biomarkers Leaders’ Summit’ in Munich in September 2018 & will Chair a Roundtable on Personalised Medicine and Adverse Events to discuss whether lessons can be learned from cancer immunotherapy and immune related adverse events to provide insight into understanding adverse events and personalised medicine and finding adverse event predictive biomarkers.
More on Prof. Cahill’s work here, https://www.researchgate.net/profile/Dolores_Cahill
Dr. Judy Mikovits BIO.
Dr. Mikovits joined NIH in 1980 as a Postdoctoral Scholar in Molecular Virology at the National Cancer Institute and began a 20-year collaboration with Frank Ruscetti, a pioneer in the field of human retro virology. She helped Dr Russetti isolate the HIV virus and link it to #AIDS in 1983. Her NIH boss Anthony Fauci delayed publication of that critical paper for 6 months to let his protégé Robert Gallo replicate, publish and claim credit. The delay in mass HIV testing let AIDS further spread around the globe and helped Fauci win promotion to director NIAID.
In 2006, Dr Mikovits became director of Whittemore Peterson Institute for Neuro-Immune Disease and collaborated with Dr Ruscetti searching for the cause of Chronic Fatigue Syndrome which suddenly became epidemic in the 1980s. The male dominated medical community dismissed CFS as psychosomatic “yuppie flu” caused when fragile females cracked in corporate jobs.
Dr. Mikovits discovered that 67% of affected women carried a virus—called Xenotropic Murine Leukemia related Virus—that appeared in healthy women only 4% of the time.
XMRV is also associated with prostate, breast, ovarian cancers, leukemia, and multiple myeloma. Many women with XMRV bore children with autism.
Hydroxychloroquine rated ‘most effective therapy’ by doctors for coronavirus: Global survey.
Drug known for treating malaria used by U.S. doctors mostly for high-risk COVID-19 patients.
Global survey – @washtimes
Thanks to Dave Cullen of Computing Forever for allowing The Platform to use his video.
Thanks to Stephen Kerr of The Irish Inquiry for allowing The Platform to use his video.
End The Lockdown & Never Lockdown Healthy People Again!